Management of Myocardial and Pericardial Diseases under COVID-19 Pandemic

Dear Colleagues,

In the last two years, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become the leading health concern worldwide. At the very beginning of the COVID-19 pandemic, it was immediately apparent that pre-existing cardiovascular diseases increase individuals’ susceptibility to SARS-CoV-2 infection and their risk of adverse outcomes due to an imbalance in ACE/ACE2 levels. Furthermore, COVID-19 itself induces  cardiovascular complications, including myocardial infarction, heart failure, arrhythmia, and myocarditis. The close relationship between SARS-CoV-2 and cardiovascular diseases raises a number of clinical questions concerning the optimal management of high-risk patients. For example, interactions between antiviral medications and other drugs could negatively affect the cardiovascular system; therefore, the interruption or compliance of chronic drug therapy, such as ACE/ARBi, as well as the side effects of vaccines on pharmacological therapies, should be considered.

This Special Issue will explore the latest findings on drug therapy for patients with concurrent cardiovascular disease and COVID-19. With this aim in mind, clinical studies, trials, reviews and meta-analyses will all be considered, particularly those with an emphasis on correct diagnosis, useful biomarkers and clinical–instrumental parameters, therapeutic approaches, risk stratification and patient monitoring during and after their infection with COVID-19.

Dr. Aneta Aleksova
Dr. Milijana Janjušević
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.